Two Directors at Cigna Group (The) bought/sold/sold after exercising options 10,052 shares at between 0.000USD and 320.000USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades b...
Summary Bupa Global - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Bupa Global, the international health insurance division of British United Provident Association Ltd (Bupa Ltd), is a provider of health insurance solutions. The company offers a wide range of medical insur...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Summary WellCare Health Plans, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights WellCare Health Plans (WellCare or 'the company') is a managed care company that offers government-sponsored managed care services to children, seniors, individuals and families wi...
We've taken a fresh look at the managed-care industry and have come away a bit more constructive on health insurers broadly. We're raising our moat ratings for UnitedHealth and Cigna to wide and narrow from narrow and none, respectively. Additionally, we're revisiting our industrywide negative moat trend outlook and bumping United to stable. For CVS and Cigna, we’ve assigned positive trend ratings, largely attributable to the competitive benefits we expect each business to achieve through thei...
We've taken a fresh look at the managed-care industry and have come away a bit more constructive on health insurers broadly. We're raising our moat ratings for UnitedHealth and Cigna to wide and narrow from narrow and none, respectively. Additionally, we're revisiting our industrywide negative moat trend outlook and bumping United to stable. For CVS and Cigna, we’ve assigned positive trend ratings, largely attributable to the competitive benefits we expect each business to achieve through thei...
We've taken a fresh look at the managed-care industry and have come away a bit more constructive on health insurers broadly. We're raising our moat ratings for UnitedHealth and Cigna to wide and narrow from narrow and none, respectively. Additionally, we're revisiting our industrywide negative moat trend outlook and bumping United to stable. For CVS and Cigna, we’ve assigned positive trend ratings, largely attributable to the competitive benefits we expect each business to achieve through thei...
The Department of Health and Human Services proposed a rule Jan. 31 that aims to untangle the opaque pricing and incentive schemes that exist under the current rebating system for prescription drugs. The rule attempts to force the pass-through of drug manufacturer discounts to plan beneficiaries at the point of sale by expressly excluding from safe-harbor provisions of the antikickback statute the discounts that are paid to Medicare Part D or Medicaid managed-care organizations. The net effect o...
The Department of Health and Human Services proposed a rule Jan. 31 that aims to untangle the opaque pricing and incentive schemes that exist under the current rebating system for prescription drugs. The rule attempts to force the pass-through of drug manufacturer discounts to plan beneficiaries at the point of sale by expressly excluding from safe-harbor provisions of the antikickback statute the discounts that are paid to Medicare Part D or Medicaid managed-care organizations. The net effect o...
The Department of Health and Human Services proposed a rule Jan. 31 that aims to untangle the opaque pricing and incentive schemes that exist under the current rebating system for prescription drugs. The rule attempts to force the pass-through of drug manufacturer discounts to plan beneficiaries at the point of sale by expressly excluding from safe-harbor provisions of the antikickback statute the discounts that are paid to Medicare Part D or Medicaid managed-care organizations. The net effect o...
Cigna reported fourth-quarter and full-year results that largely met our expectations. The company appears on-track to meet its longer-term post-integration earnings targets despite an earlier-than-expected termination of Anthem's contract with Express Scripts. This transition will now occur throughout 2019 rather than maintaining the relationship through the end of the year. While this will likely create some volatility in the firm's PBM profits over the near term, we expect the integrated firm...
Cigna reported fourth-quarter and full-year results that largely met our expectations. The company appears on-track to meet its longer-term post-integration earnings targets despite an earlier-than-expected termination of Anthem's contract with Express Scripts. This transition will now occur throughout 2019 rather than maintaining the relationship through the end of the year. While this will likely create some volatility in the firm's PBM profits over the near term, we expect the integrated firm...
On Dec. 14, Judge Reed O'Connor of the Northern District of Texas issued a ruling effectively declaring the Patient Protection and Affordable Care Act, or ACA, unconstitutional. For now, we're assuming little will change for the companies we cover in the healthcare sector over the near term as the ruling will likely make its way through the appeals process. We wouldn't be surprised to see this case as the third appearance the ACA will make in front of the U.S. Supreme Court, but the potential ti...
On Dec. 14, Judge Reed O'Connor of the Northern District of Texas issued a ruling effectively declaring the Patient Protection and Affordable Care Act, or ACA, unconstitutional. For now, we're assuming little will change for the companies we cover in the healthcare sector over the near term as the ruling will likely make its way through the appeals process. We wouldn't be surprised to see this case as the third appearance the ACA will make in front of the U.S. Supreme Court, but the potential ti...
The managed-care sector has been driven by turbulence over the past five years, and this dynamic is likely to be a major factor over the next several years. As a result, Cigna has made a major strategic move to acquire the largest independent pharmacy benefit manager, Express Scripts, in order to position itself for long-term success. Operationally, we believe this is great strategic move for Cigna, as it will acquire a wide-moat healthcare player with services that will grow ever more critical ...
Cigna was able to grow its membership book at a solid clip while keeping its medical costs in check. The firm reported 2% growth in total membership, which was driven largely by its commercial business. Cigna’s Medicare business was mainly flat, but we think the insurer did a great job managing this cohort, as the group’s medical loss ratio fell 330 basis points year over year. Despite these positives, the firm did report a moderate uptick in its operating cost ratio. The reinstatement of th...
A director at Cigna Corp gave away/sold 3,025 shares at 0.000USD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Cigna was able to grow its membership book at a solid clip while keeping its medical costs in check. The firm reported 2% growth in total membership, which was driven largely by its commercial business. Cigna’s Medicare business was mainly flat, but we think the insurer did a great job managing this cohort, as the group’s medical loss ratio fell 330 basis points year over year. Despite these positives, the firm did report a moderate uptick in its operating cost ratio. The reinstatement of th...
Cigna was able to grow its membership book at a solid clip while keeping its medical costs in check. The firm reported 2% growth in total membership, which was driven largely by its commercial business. Cigna’s Medicare business was mainly flat, but we think the insurer did a great job managing this cohort, as the group’s medical loss ratio fell 330 basis points year over year. Despite these positives, the firm did report a moderate uptick in its operating cost ratio. The reinstatement of th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.